한국어
English
日本語
中文(简体)
Regorafenib 40 mg Tablet (Regorafenib)
40mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.
Regorafenib is an anticancer ingredient that inhibits the growth of tumor cells for the treatment of malignant tumors.
MFDS ingredient code M284318
Regorafenib belongs to the class of multi-kinase inhibitors. It is primarily used for the treatment of malignant tumors and is prescribed to block the proliferation of tumor cells and angiogenesis.
Regorafenib simultaneously inhibits several protein kinases involved in the growth of tumor cells and surrounding blood vessels. This process prevents the formation of blood vessels that supply nutrients to the tumor and hinders the proliferation of tumor cells, thereby slowing down the progression of cancer.
Approved uses differ by product. Check each product's information for its actual use.
Regorafenib is a multi-target anticancer drug that simultaneously inhibits multiple kinases, blocking various signaling pathways unlike single-target inhibitors. As a result, it shows effectiveness against different types of cancer and can enhance therapeutic efficacy when administered in combination with other anticancer agents.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.